Parameters

Empagliflozin (N = 271)

DPP-4 Inhibitors (N = 331)

Rate Ratio

Incidence of DKA with metformin

Patients with events in the period, n (%)

1 (0.4)

1 (0.3)

Crude incidence rate

0.004

0.003

1.333

(95% confidence interval)

(0, 0.020)

(0, 0.017)

Treatment-adjusted incidence rate

(crude per 1000 patient-years)

1.380

1.407

0.981

(95% confidence interval)

(0.035, 7.690)

(0.036, 7.842)

Incidence of volume depletion with metformin

Patients with events in the period, n (%)

3 (1.1)

4 (1.2)

Patients without event, n (%)

268 (98.9)

327 (98.8)

Crude incidence rate

0.011

0.012

0.917

(95% confidence interval)

(0.002, 0.032)

(0.003, 0.031)

Treatment-adjusted incidence rate

(crude per 1000 patient-years)

4.141

5.630

0.736

(95% confidence interval)

(0.854, 12.101)

(1.534, 14.415)

Time from start of period to first occurrence in period (days)

76.7 ± 15

225 ± 137.9

Empagliflozin (N = 480)

DPP-4 Inhibitors (N = 420)

Rate Ratio

Incidence of volume depletion without metformin

Patients with events in the period, n (%)

3 (0.6)

3 (0.7)

Patients without event, n (%)

477 (99.4)

417 (99.3)

Crude incidence rate

0.006

0.007

0.857

(95% confidence interval)

(0.001, 0.018)

(0.001, 0.021)

Treatment-adjusted incidence rate

(crude per 1000 patient-years)

4.141

4.222

0.981

(95% confidence interval)

(0.854, 12.101)

(0.871, 12.340)

Time from start of period to first occurrence in period (days)

261.3 ± 130.8

297.7 ± 60